论文部分内容阅读
目的观察口服布拉氏酵母菌散剂对NASH大鼠的疗效及其对SR-A的影响。方法 42只雄性Sprague Dawley(SD)大鼠,随机分为正常对照组(NG,n=14)、模型组(MG,n=14)和干预组(TB,n=14);正常组给予普通饲料喂养,模型组给予高脂饲料喂养,17周起干预组给予布拉氏酵母菌散剂灌胃,24周末将所有大鼠一并处死。比较各组血清内毒素、谷丙转氨酶、谷草转氨酶;计算非酒精性脂肪性肝病评分;采用免疫荧光法测定SR-A蛋白的表达,Real time PCR法检测大鼠肝脏SR-A、TNF-αmRNA水平。结果与正常对照组相比,模型组的大鼠门冬氨酸氨基转氨酶(AST)、丙氨酸氨基转氨酶(ALT)均明显升高;干预组的大鼠AST、ALT与模型组相比均下降;模型组血清内毒素水平与正常对照组相比明显增加[(0.36±0.02)EU/mLνs(0.17±0.01)EU/mL,P<0.05];而与模型组相比,干预组血清内毒素水平减少(0.22±0.01)EU/mLνs(0.36±0.02)EU/Ml,P<0.05)。肝组织SR-A在正常对照组呈弥漫性表达,模型组肝脏的表达明显减少,干预组肝组织SR-A的表达较模型组升高。模型组的大鼠肝组织SR-A mRNA水平与正常组相比显著减少(0.52±0.32νs 1.43±0.46,P<0.05);而与模型组相比,干预组的大鼠肝组织SR-A mRNA增加(0.87±0.34νs 0.52±0.32,P<0.05)。与正常组相比,模型组的大鼠肝组织TNF-αmRNA水平明显增加(1.56±0.35νs 0.57±0.23,P<0.05);而与模型组相比,干预组的大鼠肝组织TNF-αmRNA水平减少(1.23±0.24νs 1.56±0.35,P<0.05)。结论布拉氏酵母菌散剂能够减轻肝脏脂肪变性及炎症程度,其机制可能与改善肠道菌群、减少肠源性内毒素、增加肝组织SR-A的表达有关。
Objective To observe the curative effect of oral administration of B. Cerevisiae in NASH rats and its effect on SR-A. Methods 42 male Sprague Dawley rats were randomly divided into normal control group (NG, n = 14), model group (MG, n = 14) and intervention group (TB, n = 14) The rats in the model group were fed with high-fat diet. After 17 weeks, the rats in the intervention group were given intragastric administration of B. cerevisiae powder, and all the rats were sacrificed at the end of the 24th week. Serum endotoxin, alanine aminotransferase and aspartate aminotransferase of each group were compared; score of nonalcoholic fatty liver disease was calculated; expression of SR-A protein was detected by immunofluorescence method; SR-A and TNF- Level. Results Compared with the normal control group, the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the model group were significantly increased. Compared with the model group, the levels of AST and ALT (0.36 ± 0.02) EU / mL vs (0.17 ± 0.01) EU / mL, P <0.05]. Compared with the model group, the level of serum endotoxin in the model group was significantly higher than that in the normal control group The level of toxin was decreased (0.22 ± 0.01) EU / mLνs (0.36 ± 0.02) EU / Ml, P <0.05). The expression of SR-A in hepatic tissue was diffusely expressed in normal control group, and the expression of SR-A in liver tissue of model group was significantly higher than that in model group. Compared with the model group, the SR-A mRNA level in the liver tissue of the model group was significantly decreased (0.52 ± 0.32νs 1.43 ± 0.46, P <0.05) compared with the normal group mRNA increased (0.87 ± 0.34νs 0.52 ± 0.32, P <0.05). Compared with the normal group, the level of TNF-αmRNA in the liver of the model group increased significantly (1.56 ± 0.35νs 0.57 ± 0.23, P <0.05), while compared with the model group, the level of TNF-αmRNA The level decreased (1.23 ± 0.24νs 1.56 ± 0.35, P <0.05). Conclusion Brix yeast extract can reduce hepatic steatosis and inflammation. The mechanism may be related to improving intestinal microflora, reducing intestinal endotoxin, and increasing the expression of SR-A in liver tissue.